Home | News | Events | Press | Contact  

About UseNewsletterMessage BoardsAction CenterAdvocateWalk to End Alzheimer’sShopDonate

Find your chapter:

search by state

In My Community

Weekly e-news

We will not share your information.

McGinty Conference
Text Size controlsNormal font sizeMedium font sizeLarge font size

Register online now or call 1-800-272-3900.

The McGinty Conference is Oregon’s leading research and education event that highlights Alzheimer’s disease and other dementias.  Coming up on its 19th year, the McGinty Conference honors Dr. Dean McGinty, a Portland geriatrician, an early advocate for those living with dementia and a pioneer in the Alzheimer’s family-support movement.

Since Dr. McGinty’s death in 1995, the Alzheimer’s Association Oregon Chapter has convened experts at the McGinty Conference to lead interactive sessions that focus on the many issues related to Alzheimer’s.

The McGinty Conference is geared toward individuals personally and/or professionally affected by this devastating disease. The 2017 conference will be held November 14 at the Oregon Convention Center in Portland. More than 600 participants are expected.

Rates: Professional- $100  |  Student- $50  |  Current family caregiver- free*
*A limited number of free tickets are available to family caregiver tickets through a grant from Oregon Care Partners.

                                

If you are interested in presenting or joining us as a sponsor in 2017,
contact Sarah Holland.


Thank you to our 2017 sponsors!


 

Family Caregiver Sponsor

Gold

 

 

Silver

Chancellor Health Care


 

 

Morning Keynote:

James A. Hendrix, Ph.D

James A. Hendrix, Ph.D., is director, global science initiatives, at the Alzheimer’s Association. As a member of the Medical and Scientific Relations Division, he provides leadership on specific domestic and international efforts focused on advancing the division’s science agenda. A critical element of his role is to manage industry consortia such as the Alzheimer’s Association Research Roundtable (AARR); lead the Global Biomarker Standardization Consortium; manage and direct future meeting efforts and output; and assist with the coordination of the $100 million dollar Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Study on the clinical usefulness of amyloid PET imaging.

 

Dr. Hendrix received his Ph.D. and a postdoctoral fellowship from Colorado State University. Before joining the Alzheimer’s Association, Dr. Hendrix was a pharmaceutical scientist with a focus on drug discovery for CNS diseases. Dr. Hendrix spent 18 years working at Sanofi-Aventis and predecessor companies, where he rose to level of senior director, U.S. site head for CNS research. He also spent two years working in the biotech industry with various companies, including Oligomerix, which is focused on tau for the treatment of Alzheimer’s disease.


 

Alzheimer's Association

Our vision: A world without Alzheimer's disease®.
Formed in 1980, the Alzheimer's Association is the world's leading voluntary health organization in Alzheimer's care, support and research.